Cervical cancer kills more women in South Africa than any other form of cancer. It is also more prevalent in HIV positive women than in HIV negative women. While the Department of Health has employed relatively good policies, these policies are not very well implemented. Women should be able to access a cervical cancer screening […]
Read MoreAt a press conference last month, the Treatment Action Campaign (TAC) called for price deductions on the two Human Papilloma Virus (HPV) vaccines, manufactured by GlaxoSmithKline and Merck. HPV is a common sexually transmitted infection, and some strains of the disease cause cervical cancer. In South Africa, cervical cancer is the most commonly diagnosed form […]
Read MoreToday, Tuesday 11 November, the Treatment Action Campaign hosted a press conference to draw attention to our recent global call for affordable access to HPV vaccines for developing countries. You can learn more about our HPV vaccine access campaign by clicking here. The main speakers at today’s press conference included TAC’s Women’s Rights […]
Read MoreTAC has issued the following global call for affordable access to HPV vaccines in non-OECD (developing) countries. Copies of the statement below will be delivered to representatives of Merck and GlaxoSmithKline, the manufactures and patent-holders of the Gardasil© and Ceravix© HPV vaccines , respectively, in the near future. We ask individuals and organisations to please […]
Read MoreTAC Lusikisiki has launched the first edition of “Izwi Labantu” (Voice of the People), its quarterly district newsletter. The publication is edited by Tandeka Vinjwa, a Media Literacy Practitioner at TAC’s Lusikisiki office. This edition focuses primarily on rape and gender-based violence to coincide with the District’s June GBV campaign, but it also features articles […]
Read More